Palo Santo, founded in 2020 and based in Chicago, Illinois, is a venture capital firm focused on advancing mental wellness through strategic investments. The company targets opportunities within sectors such as drug discovery and development, digital health solutions, and therapeutic services. With a commitment to addressing pressing mental health challenges, Palo Santo aims to support the development of clinically effective, affordable treatments for conditions like depression, PTSD, and addiction. The firm recognizes the fragmentation in the emerging ecosystem of mental health solutions and seeks to capitalize on high growth potential within biotech and healthcare. By backing passionate and ethical management teams, Palo Santo is positioned to play a vital role in transforming mental health care and improving access to innovative treatment options.
Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutics for psychiatric and neurological disorders, emphasizing non-hallucinogenic and rapid-acting agents. By leveraging psychedelic molecules, Psylo seeks to develop improved medications that provide effective alternatives to existing selective serotonin reuptake inhibitors (SSRIs). Its mission is to enhance treatment options for mood disorders, addiction, and certain neurological conditions, thereby broadening the scope of mental health care.
Reunion Neuroscience
Series A in 2024
Reunion Neuroscience is a clinical-stage pharmaceutical company dedicated to developing therapeutic solutions for underserved mental health conditions. The company's lead product, RE104, is a proprietary serotonergic psychedelic compound aimed at providing a fast-acting and durable antidepressant option for individuals suffering from postpartum depression and other mental health issues. Additionally, Reunion is advancing the RE200 series, which includes compounds designed for more selective serotonin receptor activity and reduced psychoactivity, potentially broadening their application in chronic treatment paradigms and various mental health conditions.
Journey Clinical
Series A in 2023
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
Gilgamesh Pharmaceuticals
Series B in 2022
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.
Sensorium Therapeutics
Venture Round in 2022
Sensorium Therapeutics is a drug discovery platform based in Boston, Massachusetts, that focuses on developing novel FDA-approved psychoactive medicines. Founded in 2021, the company utilizes an artificial intelligence product engine to discover and develop drugs targeting central nervous system diseases. By integrating historical human efficacy data from natural compounds, Sensorium Therapeutics aims to create new medicines characterized by innovative pharmacology and improved clinical success rates. This approach enables pharmaceutical companies to enhance their drug development processes effectively.
Kanna Health
Convertible Note in 2022
Kanna Health is a preclinical stage biotechnology company focused on developing innovative therapeutics derived from kanna, or Sceletium tortuosum, a medicinal succulent used for centuries by the San hunter-gatherers of South Africa. The company aims to address significant unmet needs in sexual and mental health through its lead candidate, KH-001, which is based on alkaloids found in kanna. This candidate is designed to enhance mood and performance in men, offering potential treatments that are both effective and affordable.
Fluence
Seed Round in 2021
Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend.
Wavepaths
Seed Round in 2021
Wavepaths is a London-based company established in 2018 that focuses on creating innovative tools for psychedelic therapy aimed at facilitating inner exploration and personal transformation. The company develops a unique application that auto-generates individualized soundtracks for drug-free therapy sessions, integrating immersive media with advancements in intelligent technology and psychedelic science. By combining these elements, Wavepaths offers mobile tools and physical environments designed to help users reconnect with their inner resources, fostering meaningful introspection and emotional reconnection. The company's work lies at the intersection of information technology, healthcare, and personal health, emphasizing accessibility and personal growth through therapeutic experiences.
Delix Therapeutics
Series A in 2021
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.
Journey Clinical
Seed Round in 2021
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
Beckley Psytech
Series B in 2021
Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.
Ksana Health
Seed Round in 2021
Ksana Health is a company based in Eugene, Oregon, founded in 2019, that specializes in digital mental health solutions. The company has developed a platform aimed at collecting and transferring mental health data from users to healthcare practitioners via an app. This platform provides personalized behavioral insights and just-in-time interventions, enabling continuous remote monitoring of patients. Additionally, it offers digital therapeutics designed to enhance mental health outcomes. Through its innovative approach, Ksana Health seeks to improve the accessibility and effectiveness of mental health care.
Eleusis
Series A in 2020
Eleusis is a clinical stage life science company focused on developing psychedelic drug therapies aimed at addressing unmet medical needs in psychiatry and beyond. The company is dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly known as psychedelics, while managing their psychoactive effects. Eleusis is working on a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment option for depression. This innovation seeks to provide healthcare providers and pharmaceutical companies with alternative solutions that can meet a wide range of patient needs that are not adequately addressed by traditional therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.